Abstract
Background: Prevention and treatment of chronic inflammatory diseases require effective and low-toxic medicines. Molecular hybridization is an effective strategy to enhance the biological activity of new compounds. Triterpenoid scaffolds are in the focus of attention owing to their anti-inflammatory, antiviral, antiproliferative, and immunomodulatory activities. Heteroprostanoids have different pleiotropic effects in acute and chronic inflammatory processes.
Objective: The study aimed to develop structurally new and low toxic anti-inflammatory agents via hybridization of betulinic acid with azaprostanoic acids.
Methods: A series of betulinic acid-azaprostanoid hybrids was synthesized. The synthetic pathway included the transformation of betulin via Jones' oxidation into betulonic acid, reductive amination of the latter and coupling obtained by 3β-amino-3-deoxybetulinic acid with the 7- or 13-azaprostanoic acids and their homo analogues. The hybrids 1-9 were investigated in vivo on histamine-, formalin- and concanavalin A-induced mouse paw edema models and two models of pain - the acetic acid-induced abdominal writhing and the hotplate test. The hybrids were in vitro evaluated for cytotoxic activity on cancer (MCF7, U- 87 MG) and non-cancer humane cell lines.
Results: In the immunogenic inflammation model, the substances showed a pronounced anti-inflammatory effect, which was comparable to that of indomethacin. In the models of the exudative inflammation, none of the compounds displayed a statistically significant effect. The hybrids produced weak or moderate analgesic effects. All the agents revealed low cytotoxicity on human immortalized fibroblasts and cancer cell lines compared with 3β- amino-3-deoxybetulinic acid and doxorubicin.
Conclusion: The results indicate that the principal anti-inflammatory effect of hybrids is substantially provided with the triterpenoid scaffold and in some cases with the azaprostanoid scaffold, but the latter makes a significant contribution to reducing the toxicity of hybrids. Hybrid 1 is of interest as a potent low toxic agent against immune-mediated inflammation.
Keywords: Analgesic activity, anti-inflammatory activity, azaprostanoids, betulinic acid, cytotoxicity, hybrids.
Graphical Abstract
[http://dx.doi.org/10.1016/j.bcp.2015.03.014] [PMID: 25850000]
[http://dx.doi.org/10.1016/j.cell.2010.02.043] [PMID: 20303881]
[http://dx.doi.org/10.3390/molecules21101321] [PMID: 27706084]
[PMID: 16523720]
[http://dx.doi.org/10.1016/j.ejmech.2018.01.011] [PMID: 29353722]
[http://dx.doi.org/10.1016/j.jep.2009.12.045] [PMID: 20079412]
[http://dx.doi.org/10.1002/med.10053] [PMID: 14595673]
[http://dx.doi.org/10.1016/j.ejps.2015.01.001] [PMID: 25585354]
[http://dx.doi.org/10.3390/molecules21091206] [PMID: 27618005]
[http://dx.doi.org/10.1016/j.intimp.2014.09.021] [PMID: 25281393]
[http://dx.doi.org/10.1007/BF02994763] [PMID: 14723345]
[http://dx.doi.org/10.2174/138920112798868719] [PMID: 21466427]
[http://dx.doi.org/10.1194/jlr.R800094-JLR200] [PMID: 19095631]
[http://dx.doi.org/10.1530/REP-13-0587] [PMID: 24890751]
[http://dx.doi.org/10.1038/9550] [PMID: 10371510]
[http://dx.doi.org/10.1038/34178] [PMID: 9422508]
[http://dx.doi.org/10.1038/34184] [PMID: 9422509]
[http://dx.doi.org/10.1038/47520] [PMID: 10638762]
[http://dx.doi.org/10.1070/RC1992v061n02ABEH000943]
[http://dx.doi.org/10.1016/j.ejmech.2018.03.057] [PMID: 29605809]
[http://dx.doi.org/10.1016/j.ejmech.2016.08.039] [PMID: 27598238]
[http://dx.doi.org/10.1016/j.steroids.2016.08.002] [PMID: 27500691]
[http://dx.doi.org/10.1007/s10600-017-2028-x]
[http://dx.doi.org/10.1016/j.bmc.2009.05.059] [PMID: 19524443]
[PMID: 13035677]
[http://dx.doi.org/10.1016/0022-1759(83)90303-4] [PMID: 6606682]
[http://dx.doi.org/10.1016/j.ejps.2006.04.006] [PMID: 16716572]
[http://dx.doi.org/10.1080/00397919708006099]
[http://dx.doi.org/10.1016/S0960-894X(98)00295-9] [PMID: 9873420]
[http://dx.doi.org/10.1016/0014-2999(95)00169-L]